## **Tripod checklist: Model Prediction & Validation**

Downloaded from: <a href="https://www.tripod-statement.org/resources/">https://www.tripod-statement.org/resources/</a>

Topic	Item*		Checklist item	Thesis' section			
Title & Abstract							
Title	1	D; V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Title			
Abstract	2	D; V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Abstract			
Introduction	Introduction						
Background & Objectives	3a	D; V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Introduction: Sections 1.1, 1.2			
	3b	D; V	Specify the objectives, including whether the study describes the development or validation of the model or both.	Introduction: Section 1.3			
Methods							
Source of data	4a	D; V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	Methods: Section 2.1			
	4b	D; V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Methods: Section 2.3			
Participants	5a	D; V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Methods: Section 2.1			
	5b	D; V	Describe eligibility criteria for participants	Not available (no information was available			

				about eligibility criteria for patients to be included/excluded from PROM datasets)
	5c	D; V	Give details of treatments received, if relevant.	Not applicable
Outcome	6a	D; V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Methods: Section 2.4
	6b	D; V	Report any actions to blind assessment of the outcome to be predicted.	Not applicable
Predictors	7a	D; V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Methods: Section 2.3, Appendices: Appendix 12
	7b	D; V	Report any actions to blind assessment of predictors for the outcome and other predictors.	Not applicable
Sample size	8	D; V	Explain how the study size was arrived at.	Not available (no attempt was done to estimate an optimal sample size)
Missing data	9	D; V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Methods: Section 2.3
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Methods: Section 2.3; Appendix 12
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Methods: Section 2.6.2; Appendix 1
	10c	V	For validation, describe how the predictions were calculated.	Methods: Section 2.6.3
	10d	D; V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Methods: Section 2.6.3
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	Not applicable
Risk groups	11	D; V	Provide details on how risk groups were created, if done.	Not applicable

12	V	For validation, identify any differences from the development data	Not available			
		in setting, eligibility criteria, outcome, and predictors.	Trot available			
Results						
13a	D; V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Results: Sections 3.1 and 3.2			
13b	D; V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Results: Section 3.2; Appendices 6-9, 13, 14			
13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Results: Section 3.2			
14a	D	Specify the number of participants and outcome events in each analysis	Results: Section 3.2			
14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Not applicable			
15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Partially reported. Predictors' importance for trained/tested models is available in Figure 11			
15b	D	Explain how to the use the prediction model.	Not applicable			
16	D; V	Report performance measures (with CIs) for the prediction model.	Partially reported. Results: Section 3.3			
17	V	If done, report the results from any model updating (i.e., model specification, model performance).	Not applicable			
Discussion						
18	D; V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Discussion: Section 4.5			
	13b 13c 14a 14b 15a 15b 16 17	13a D; V  13b D; V  13c V  14a D  14b D  15b D  16 D; V  17 V	13a D; V Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.  13b D; V Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.  For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).  Specify the number of participants and outcome events in each analysis  14b D If done, report the unadjusted association between each candidate predictor and outcome.  Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).  15b D Explain how to the use the prediction model.  17 V Report performance measures (with Cls) for the prediction model.  18 D: V Discuss any limitations of the study (such as nonrepresentative)			

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	Discussion: Sections 4.1, 4.2, 4.3		
	19b	D; V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence	Discussion		
Other information						
Supplementary information	21	D; V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Appendices		
Funding	22	D; V	Give the source of funding and the role of the funders for the present study.	Not applicable		

<sup>\*</sup>Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V.